C Simpson1,2, D Jayaramaraju3, D Agraharam3, S Gudipati4, R Shanmuganathan3, P V Giannoudis4,5. 1. Academic Department of Trauma and Orthopaedics, Leeds General Infirmary, Great George Street, Leeds, England, UK. christopher.simpson@doctors.org.uk. 2. , 35 Potters Lane, East Leake, Loughborough, LE12 6NQ, England, UK. christopher.simpson@doctors.org.uk. 3. Academic Department of Trauma and Orthopaedics, Ganga Medical Centre and Hospitals, Coimbatore, India. 4. Academic Department of Trauma and Orthopaedics, Leeds General Infirmary, Great George Street, Leeds, England, UK. 5. Leeds Biomedical Research Unit, Chappell Allerton Hospital, Leeds, England, UK.
Abstract
PURPOSE: Diabetes has long been known to have an impact on bone repair. More recently, however, most diabetic patients receive medications to normalise this hyperglycaemic environment. To date, no studies have investigated the effects of diabetic medications on fracture healing in humans. METHOD: Patients were identified from two tertiary trauma centres. Inclusion criteria were adult patients having sustained a closed diaphyseal femoral or tibial fracture, treated surgically. Exclusion criteria were open, pathological or peri-prosthetic fractures, and patients having sustained polytrauma. Matched non-diabetic controls were identified, matched for age, sex, fracture classification and osteosynthesis. Output measures were: time to callus first appearance, bridging of involved cortices and time to union, along with the eventual outcome: union/non-union. RESULTS: A total of 36 (25 males) eligible patients were identified with a control group of 166 patients (138 males). ANOVA demonstrated class of medication to have a significant effect at two of the three time points and on the eventual outcome. Multiple regression analysis also demonstrated significant impact (p = 0.02). CONCLUSION: All classes of medication demonstrated anti-osteogenic effects compared to the control cohort. Biguanides demonstrated this in contrast to the in vitro evidence to date. Sulphonylureas demonstrated this to a greater extent; however, no in vitro evidence is available for comparison within this class. Clinicians should be aware of these delays in bone healing when treating diabetic patients and aim for optimal blood glucose control until such time as further research can be undertaken.
PURPOSE:Diabetes has long been known to have an impact on bone repair. More recently, however, most diabeticpatients receive medications to normalise this hyperglycaemic environment. To date, no studies have investigated the effects of diabetic medications on fracture healing in humans. METHOD:Patients were identified from two tertiary trauma centres. Inclusion criteria were adult patients having sustained a closed diaphyseal femoral or tibial fracture, treated surgically. Exclusion criteria were open, pathological or peri-prosthetic fractures, and patients having sustained polytrauma. Matched non-diabetic controls were identified, matched for age, sex, fracture classification and osteosynthesis. Output measures were: time to callus first appearance, bridging of involved cortices and time to union, along with the eventual outcome: union/non-union. RESULTS: A total of 36 (25 males) eligible patients were identified with a control group of 166 patients (138 males). ANOVA demonstrated class of medication to have a significant effect at two of the three time points and on the eventual outcome. Multiple regression analysis also demonstrated significant impact (p = 0.02). CONCLUSION: All classes of medication demonstrated anti-osteogenic effects compared to the control cohort. Biguanides demonstrated this in contrast to the in vitro evidence to date. Sulphonylureas demonstrated this to a greater extent; however, no in vitro evidence is available for comparison within this class. Clinicians should be aware of these delays in bone healing when treating diabeticpatients and aim for optimal blood glucose control until such time as further research can be undertaken.
Authors: Kimberly A Kyle; Thomas L Willett; Laurie L Baggio; Daniel J Drucker; Marc D Grynpas Journal: Endocrinology Date: 2010-12-22 Impact factor: 4.736
Authors: Andrew Grey; Mark Bolland; Greg Gamble; Diana Wattie; Anne Horne; James Davidson; Ian R Reid Journal: J Clin Endocrinol Metab Date: 2007-01-30 Impact factor: 5.958
Authors: Ronaldo B Santana; Lei Xu; Hermik Babakhanlou Chase; Salomon Amar; Dana T Graves; Philip C Trackman Journal: Diabetes Date: 2003-06 Impact factor: 9.461
Authors: Rayyan A Kayal; Jazia Alblowi; Erin McKenzie; Nanarao Krothapalli; Lee Silkman; Louis Gerstenfeld; Thomas A Einhorn; Dana T Graves Journal: Bone Date: 2008-10-29 Impact factor: 4.398
Authors: Carlos Marin; Frank P Luyten; Bart Van der Schueren; Greet Kerckhofs; Katleen Vandamme Journal: Front Endocrinol (Lausanne) Date: 2018-01-24 Impact factor: 5.555